Immunogenicity and Safety Study of GSK Biologicals (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years.
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2018
At a glance
- Drugs GSK 1536489A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 17 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 17 Aug 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2010 New trial record